| Filed On | Filing |
|---|---|
| 13 Nov 2025 |
8-K/A: Results of Operations and Financial Condition
Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML |
| 29 May 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Enliven Therapeutics, Inc. (the “Company”) is filing this amendment to its Current Report on Form 8-K filed on April 9, 2024, which reported that the Company’s Board of Directors (the “Board”) had appointed Lori Kunkel as a new director ... |
| 21 Mar 2023 |
8-K/A: Regulation FD Disclosure; Other Events
Financials Statements as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021 |
| 16 Nov 2022 |
8-K/A: Financial Statements and Exhibits
On November 10, 2022 (the “Closing Date”), IMARA Inc. (the “Company”) completed the previously announced transaction providing for the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program (the “A... |
Loading...
